V

Virax Biolabs Group Ltd
NASDAQ:VRAX

Watchlist Manager
Virax Biolabs Group Ltd
NASDAQ:VRAX
Watchlist
Price: 0.37 USD 5.71%
Market Cap: 1.6m USD

Intrinsic Value

VRAX doesn't have a meaningful market cap.

The intrinsic value of one VRAX stock under the Base Case scenario is 0.56 USD. Compared to the current market price of 0.37 USD, Virax Biolabs Group Ltd is Undervalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VRAX Intrinsic Value
0.56 USD
Undervaluation 33%
Intrinsic Value
Price
V
Worst Case
Base Case
Best Case

Valuation History
Virax Biolabs Group Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about VRAX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is VRAX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Virax Biolabs Group Ltd.

Explain Valuation
Compare VRAX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about VRAX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Virax Biolabs Group Ltd

Balance Sheet Decomposition
Virax Biolabs Group Ltd

Current Assets 4.1m
Cash & Short-Term Investments 3.3m
Receivables 175.7k
Other Current Assets 628.2k
Non-Current Assets 1.6m
PP&E 1.6m
Current Liabilities 365.5k
Accounts Payable 42.4k
Accrued Liabilities 61.2k
Short-Term Debt 195.6k
Other Current Liabilities 66.3k
Non-Current Liabilities 37.6k
Long-Term Debt 276k
Other Non-Current Liabilities -238.4k
Efficiency

Free Cash Flow Analysis
Virax Biolabs Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Virax Biolabs Group Ltd

Revenue
3k USD
Cost of Revenue
-48.3k USD
Gross Profit
-45.3k USD
Operating Expenses
-5.8m USD
Operating Income
-5.9m USD
Other Expenses
225.9k USD
Net Income
-5.6m USD
Fundamental Scores

VRAX Profitability Score
Profitability Due Diligence

Virax Biolabs Group Ltd's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

Negative 3Y Average Gross Margin
Negative 3Y Average Net Margin
Negative Gross Margin
Negative 3Y Average Operating Margin
10/100
Profitability
Score

Virax Biolabs Group Ltd's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

VRAX Solvency Score
Solvency Due Diligence

Virax Biolabs Group Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
63/100
Solvency
Score

Virax Biolabs Group Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRAX Price Targets Summary
Virax Biolabs Group Ltd

There are no price targets for VRAX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Virax Biolabs Group Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for VRAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one VRAX stock?

The intrinsic value of one VRAX stock under the Base Case scenario is 0.56 USD.

Is VRAX stock undervalued or overvalued?

Compared to the current market price of 0.37 USD, Virax Biolabs Group Ltd is Undervalued by 33%.

Back to Top